ID   SB-HSA
AC   CVCL_0C95
SY   SB; SBHSA
DR   GEO; GSM1122229
DR   Wikidata; Q54952156
RX   PubMed=15064773;
RX   PubMed=15140399;
RX   PubMed=22594682;
RX   PubMed=24582862;
RX   PubMed=25190452;
RX   PubMed=26842912;
RX   PubMed=28029283;
RX   PubMed=30601866;
RX   PubMed=31175136;
CC   Characteristics: Established from a xenograft produced in bg/nu/XID nude mice (PubMed=15064773).
CC   Doubling time: ~20-24 hours (PubMed=15064773).
CC   Sequence variation: Mutation; VGNC; VGNC:84862; EP300; Simple; p.Asn1570fs (c.4704dupG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:44555; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:47719; TP53; Simple; p.Ala150fs (c.447delG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:47719; TP53; Simple; p.Leu184Phe (c.550C>T); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Breed/subspecies: German Shepherd; VBO=VBO_0200577.
ST   Source(s): PubMed=31175136
ST   Dog FHC2010: 239
ST   Dog FHC2054: 156,164
ST   Dog FHC2079: 275
ST   Dog PEZ1: 115,119
ST   Dog PEZ3: 119,131
ST   Dog PEZ5: 103,107
ST   Dog PEZ6: 172,183
ST   Dog PEZ8: 228
ST   Dog PEZ12: 270,274
ST   Dog PEZ20: 176
DI   NCIt; C122783; Canine hemangiosarcoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   9Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-04-25; Version: 20
//
RX   PubMed=15064773; DOI=10.1038/labinvest.3700080;
RA   Fosmire S.P., Dickerson E.B., Scott A.M., Bianco S.R.,
RA   Pettengill M.J., Meylemans H.A., Padilla M.L., Frazer-Abel A.A.,
RA   Akhtar N., Getzy D.M., Wojcieszyn J., Breen M., Helfand S.C.,
RA   Modiano J.F.;
RT   "Canine malignant hemangiosarcoma as a model of primitive angiogenic
RT   endothelium.";
RL   Lab. Invest. 84:562-572(2004).
//
RX   PubMed=15140399; DOI=10.1593/neo.03334; PMCID=PMC1502086;
RA   Akhtar N., Padilla M.L., Dickerson E.B., Steinberg H., Breen M.,
RA   Auerbach R., Helfand S.C.;
RT   "Interleukin-12 inhibits tumor growth in a novel angiogenesis canine
RT   hemangiosarcoma xenograft model.";
RL   Neoplasia 6:106-116(2004).
//
RX   PubMed=22594682; DOI=10.1111/j.1476-5829.2012.00335.x;
RA   Lyles S.E., Milner R.J., Kow K., Salute M.E.;
RT   "In vitro effects of the tyrosine kinase inhibitor, masitinib
RT   mesylate, on canine hemangiosarcoma cell lines.";
RL   Vet. Comp. Oncol. 10:223-235(2012).
//
RX   PubMed=24582862; DOI=10.1016/j.yexcr.2014.02.020; PMCID=PMC4256199;
RA   Kim J.-H., Frantz A.M., Anderson K.L., Graef A.J., Scott M.C.,
RA   Robinson S., Sharkey L.C., O'Brien T.D., Dickerson E.B.,
RA   Modiano J.F.;
RT   "Interleukin-8 promotes canine hemangiosarcoma growth by regulating
RT   the tumor microenvironment.";
RL   Exp. Cell Res. 323:155-164(2014).
//
RX   PubMed=25190452; DOI=10.1186/s12917-014-0184-9; PMCID=PMC4172958;
RA   Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.;
RT   "The long-acting COX-2 inhibitor mavacoxib (Trocoxil TM) has
RT   anti-proliferative and pro-apoptotic effects on canine cancer cell
RT   lines and cancer stem cells in vitro.";
RL   BMC Vet. Res. 10:184.1-184.11(2014).
//
RX   PubMed=26842912; DOI=10.1111/vco.12197;
RA   Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N.,
RA   Guth A., Regan D.P., Dow S.W.;
RT   "Immune regulation of canine tumour and macrophage PD-L1 expression.";
RL   Vet. Comp. Oncol. 15:534-549(2017).
//
RX   PubMed=28029283; DOI=10.2460/ajvr.78.1.69; PMCID=PMC5299388;
RA   Witter L.E., Gruber E.J., Lean F.Z.-X., Stokol T.;
RT   "Evaluation of procoagulant tissue factor expression in canine
RT   hemangiosarcoma cell lines.";
RL   Am. J. Vet. Res. 78:69-79(2017).
//
RX   PubMed=30601866; DOI=10.1371/journal.pone.0210297; PMCID=PMC6314605;
RA   Dowling M., Samuelson J., Fadl-Alla B.A., Pondenis H.C., Byrum M.,
RA   Barger A.M., Fan T.M.;
RT   "Overexpression of prostate specific membrane antigen by canine
RT   hemangiosarcoma cells provides opportunity for the molecular detection
RT   of disease burdens within hemorrhagic body cavity effusions.";
RL   PLoS ONE 14:e0210297.1-e0210297.20(2019).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole-exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//